Biopharmaceutical company Innovent Biologics Inc (HKEX:01801) reported on Wednesday the start of treatment of the first patient with wet age-related macular degeneration (wet AMD) in a Phase I clinical trial of IBI302.
AMD, a disease which results in progressive worsening of vision in the centre of the visual field of the macular retina, is one of the leading causes of severe vision loss and blindness in people aged 50 and above in the developed world. It can be divided into dry AMD and wet AMD according to clinical manifestations and pathobiology.
IBI302 is a novel recombinant fully human bi-specific fusion protein targeting both vascular endothelium growth factor (VEGF) and complement proteins. VEGF plays a fundamental role in choroidal neovascularization. The N-arm can bind to the VEGF family to block VEGF-mediated signaling pathways, inhibit vascular epithelium proliferation and angiogenesis and reduce vascular leakage. The C-arm can inhibit the activation of the classic and alternative pathways of complement through the specific binding of complement components 3b and 4b and reduce the inflammatory response mediated by complement proteins.
The Phase I study of IBI302 is an open-label, single-centre, dose escalation clinical trial that will evaluate the safety and tolerability of IBI302 in a single intravitreal injection in patients with wet AMD.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins